"Audentes has firmly established itself as a leader in the emerging field of gene therapy and is well-positioned for meaningful upcoming catalysts, including preliminary efficacy data from its lead XLMTM program, the initiation of a Phase 1/2 study in its Crigler-Najjar program and the advancement of its Pompe disease and cardiac gene therapy programs. I look forward to working closely with the Audentes board and management team during what promises to be an exciting 2018." About Audentes Therapeutics, Inc. Audentes Therapeutics (Nasdaq: BOLD ) is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases.